N@N

Gregory Renza Reiterated (ACAD) at Buy and Held Target at $27 on, May 9th, 2023

Gregory Renza of RBC Capital, Reiterated "ACADIA Pharmaceuticals Inc." (ACAD) at Buy and Held Target at $27 on, May 9th, 2023.

Gregory has made no other calls on ACAD in the last 4 months.

There are 8 other peers that have a rating on ACAD. Out of the 8 peers that are also analyzing ACAD, 6 agree with Gregory's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Uy Ear of "Mizuho" Reiterated at Hold and Held Target at $20 on, Friday, April 14th, 2023
• Julio Romero of "JP Morgan" Maintained at Hold with Increased Target to $21 on, Monday, March 20th, 2023
• Tazeen Ahmad of "B of A Securities" Maintained at Hold and Held Target at $23 on, Tuesday, March 14th, 2023
• Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $20 on, Tuesday, March 14th, 2023
• Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $20 on, Wednesday, March 1st, 2023
• Jason West of "JMP Securities" Maintained at Hold with Decreased Target to $22 on, Tuesday, February 28th, 2023

These are the ratings of the 2 analyists that currently disagree with Gregory

---

• Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $26 on, Tuesday, March 14th, 2023
• Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $33 on, Tuesday, March 14th, 2023

Contributing Sources

---